Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Priming the Tumour MicroEnvironment for Effective Treatment With Immunotherapy in Locally Advanced Rectal Cancer A Phase II Trial of Durvalumab (MEDI 4736) in Combination With Extended Neoadjuvant Regimens in Rectal Cancer

NCT04621370 is registered in ClinicalTrials.gov with Liz-Anne Lewsley as lead sponsor.

NCT NCT04621370
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04621370 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Priming the Tumour MicroEnvironment for Effective Treatment With Immunotherapy in Locally Advanced Rectal Cancer A Phase II Trial of Durvalumab (MEDI 4736) in Combination With Extended Neoadjuvant Regimens in Rectal Cancer
Lead sponsor
Liz-Anne Lewsley
Phase
Phase 2
Overall status
Unknown status
Start date
December 7, 2020
Completion date
December 31, 2025
Enrollment
48 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

rectal adenocarcinoma, rectal cancer, rectal neoplasms